» Articles » PMID: 17259403

Type 2 Diabetes-associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program

Overview
Journal Diabetes
Specialty Endocrinology
Date 2007 Jan 30
PMID 17259403
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The common polymorphisms KCNJ11 E23K and ABCC8 A1369S have been consistently associated with type 2 diabetes. We examined whether these variants are also associated with progression from impaired glucose tolerance (IGT) to diabetes and responses to preventive interventions in the Diabetes Prevention Program. We genotyped both variants in 3,534 participants and performed Cox regression analysis using genotype, intervention, and their interactions as predictors of diabetes incidence over approximately 3 years. We also assessed the effect of genotype on insulin secretion and insulin sensitivity at 1 year. As previously shown in other studies, lysine carriers at KCNJ11 E23K had reduced insulin secretion at baseline; however, they were less likely to develop diabetes than E/E homozygotes. Lysine carriers were less protected by 1-year metformin treatment than E/E homozygotes (P < 0.02). Results for ABCC8 A1369S were essentially identical to those for KCNJ11 E23K. We conclude that the lysine variant in KCNJ11 E23K leads to diminished insulin secretion in individuals with IGT. Given our contrasting results compared with case-control analyses, we hypothesize that its effect on diabetes risk may occur before the IGT-to-diabetes transition. We further hypothesize that the diabetes-preventive effect of metformin may interact with the impact of these variants on insulin regulation.

Citing Articles

MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.

Flowers E, Aouizerat B, Kanaya A, Florez J, Gong X, Zhang L J Clin Endocrinol Metab. 2022; 108(6):e306-e312.

PMID: 36477577 PMC: 10188307. DOI: 10.1210/clinem/dgac714.


Variants of may be Linked to Poor Response to Metformin.

Paz-Pacheco E, Nevado Jr J, C Cutiongco-de la Paz E, Jasul Jr G, Aman A, Ribaya E J Endocr Soc. 2022; 6(8):bvac092.

PMID: 35854978 PMC: 9278830. DOI: 10.1210/jendso/bvac092.


The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.

Kahn S, Chen Y, Esser N, Taylor A, van Raalte D, Zraika S Endocr Rev. 2021; 42(5):528-583.

PMID: 34180979 PMC: 9115372. DOI: 10.1210/endrev/bnab021.


A review of clinical pharmacogenetics Studies in African populations.

Radouani F, Zass L, Hamdi Y, da Rocha J, Sallam R, Abdelhak S Per Med. 2020; 17(2):155-170.

PMID: 32125935 PMC: 8093600. DOI: 10.2217/pme-2019-0110.


Gene-lifestyle interaction on risk of type 2 diabetes: A systematic review.

Dietrich S, Jacobs S, Zheng J, Meidtner K, Schwingshackl L, Schulze M Obes Rev. 2019; 20(11):1557-1571.

PMID: 31478326 PMC: 8650574. DOI: 10.1111/obr.12921.


References
1.
. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care. 2000; 23(11):1619-29. PMC: 1360735. DOI: 10.2337/diacare.23.11.1619. View

2.
Hsieh F, Lavori P . Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2001; 21(6):552-60. DOI: 10.1016/s0197-2456(00)00104-5. View

3.
Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanne-Parikka P . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18):1343-50. DOI: 10.1056/NEJM200105033441801. View

4.
Gloyn A, Hashim Y, Ashcroft S, Ashfield R, Wiltshire S, Turner R . Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med. 2001; 18(3):206-12. DOI: 10.1046/j.1464-5491.2001.00449.x. View

5.
Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. PMC: 1370926. DOI: 10.1056/NEJMoa012512. View